Toronto-based Future Fertility, which has built an AI platform for objective egg quality assessment, has closed a $4.1 million Series A led by M Ventures (the corporate venture capital arm of Merck KGaA) and Whitecap Venture Partners, with participation from Sandpiper Ventures, Gaingels, and Jolt VC. The company previously raised a seed round in 2022.
The company addresses a fundamental gap in fertility care: despite egg quality being one of the most important drivers of reproductive success, there has historically been no objective, clinically validated method for assessing it. Future Fertility’s deep learning tools – VIOLET (egg freezing), MAGENTA (IVF), and ROSE (egg donation) – are trained on more than 650,000 oocyte images and deployed in over 300 clinics across 35 countries, including partnerships with IVI RMA, Eugin Group, FertGroup Medicina Reproductiva, and Kato Ladies Clinic in Japan.
“Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through,” said CEO Christine Prada. “Every patient deserves objective data, not just a best guess, to support better at critical moments in their care. This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”
The funding will accelerate commercial expansion into Asia-Pacific and support U.S. market entry, including planned FDA 510(k) clearance for additional products. The company is also developing a broader AI platform spanning egg assessment through to embryo transfer, covering the full IVF journey. ROSE is already available in the U.S. under an FDA 513(g) determination.
Research shows that approximately 50% of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely even though cumulative success rates improve significantly with multiple cycles. By providing earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients about realistic expectations and next steps.
“Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration,” said Oliver Hardick, investment director at M Ventures. “We believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalized standard of care in fertility treatment.”
The company’s evidence base includes seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, along with more than 70 scientific abstracts presented at conferences globally.
